Suputtamongkol 2008.

Methods	RCT. Leght of follow‐up: 2 to 3 weeks.
Participants	Number randomized: 42 participants. Inclusion criteria: Adult people (included immunocompromised patients: 5 immunosuppressive drugs users, 3 AIDS/HIV patients, 2 hematological malignancy patients). Aged 22 to 87 years old, were recruited if characteristic rhabditiform larvae of S. stercoralis were present on faecal microscopy. Baseline signs and symptoms such as abdominal pain, diarrhoea and nausea/vomiting were recorded. Exclusion criteria: a history of allergic reaction to either trial medication, treatment in the month prior to the trial with any drug known to have anti‐Strongyloides activity, pregnancy or lactation, and any suggestion of disseminated strongyloidiasis.
Interventions	Ivermectin 200 μg/kg single oral dose (parenteral veterinary preparation) (N = 21) and albendazole 800 mg daily for 7 days (N = 21).
Outcomes	Drug efficacy: negative stool samples 7 days. Adverse events were reported.
Notes	Diagnostic method: smear examination and formol‐ether concentration. Place: Thailand, Siriraj Hospital.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	High risk	Patients were randomly allocated. We do not know how the randomization was done.
Allocation concealment (selection bias)	High risk	We do not know how allocation was concealed. Probably not done.
Blinding of participants and personnel (performance bias) Cure overall	Low risk	No blinding of participants and personnel but we don't believe this will introduce bias.
Blinding of participants and personnel (performance bias) Adverse events overall	High risk	No blinding of participants and personnel and the outcome is likely to be influenced by lack of blinding.
Blinding of outcome assessment (detection bias) Cure overall	Low risk	No blinding, but we judge that the outcome measurement is unlikely to be influenced by lack of blinding.
Blinding of outcome assessment (detection bias) Adverse events overall	High risk	No blinding, and the outcome measurement is likely to be influenced by lack of blinding.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Five patients were lost from the albendazole group and three from the ivermectin group, during median follow‐up periods of 13 days (range 6 to 85 days) and 19 days (3 to 117 days), respectively. Per‐protocol analysis.
Selective reporting (reporting bias)	Low risk	No protocol provided, but given the outcomes nominated in the methods section, all pre‐specified outcomes were reported.
Other bias	Low risk	No additional biases were identified.